Abstract
This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 710-717 |
| Number of pages | 8 |
| Journal | European Journal of Cancer |
| Volume | 43 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Mar 2007 |
Fingerprint
Keywords
- Cisplatin
- Erythropoietin
- Neurophysiology
- Pathology
- Peripheral neuropathy
- Rat
- Tumour growth
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Cisplatin-induced peripheral neuropathy : Neuroprotection by erythropoietin without affecting tumour growth. / Bianchi, Roberto; Gilardini, Alessandra; Rodriguez-Menendez, Virginia; Oggioni, Norberto; Canta, Annalisa; Colombo, Tina; Michele, Giulia De; Martone, Sara; Sfacteria, Alessandra; Piedemonte, Giuseppe; Grasso, Giovanni; Beccaglia, Patrizia; Ghezzi, Pietro; D'Incalci, Maurizio; Lauria, Giuseppe; Cavaletti, Guido.
In: European Journal of Cancer, Vol. 43, No. 4, 03.2007, p. 710-717.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplatin-induced peripheral neuropathy
T2 - Neuroprotection by erythropoietin without affecting tumour growth
AU - Bianchi, Roberto
AU - Gilardini, Alessandra
AU - Rodriguez-Menendez, Virginia
AU - Oggioni, Norberto
AU - Canta, Annalisa
AU - Colombo, Tina
AU - Michele, Giulia De
AU - Martone, Sara
AU - Sfacteria, Alessandra
AU - Piedemonte, Giuseppe
AU - Grasso, Giovanni
AU - Beccaglia, Patrizia
AU - Ghezzi, Pietro
AU - D'Incalci, Maurizio
AU - Lauria, Giuseppe
AU - Cavaletti, Guido
PY - 2007/3
Y1 - 2007/3
N2 - This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.
AB - This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.
KW - Cisplatin
KW - Erythropoietin
KW - Neurophysiology
KW - Pathology
KW - Peripheral neuropathy
KW - Rat
KW - Tumour growth
UR - http://www.scopus.com/inward/record.url?scp=33947703740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947703740&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.09.028
DO - 10.1016/j.ejca.2006.09.028
M3 - Article
C2 - 17251006
AN - SCOPUS:33947703740
VL - 43
SP - 710
EP - 717
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -